Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
FDA Grants Fast Track to World’s First Therapy for Diffuse Gastric Cancer
Details : SIGX1094, an investigational small molecule and the first targeted drug candidate for diffuse gastric cancer, has received fast track designation from the FDA.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2025
Organoid-AI Drug Candidate Doses First Patient in Diffuse Gastric Cancer
Details : Sigx1094 targets FAK and YAP, which are crucial for cancer cell survival and proliferation, sigx1094 aims to disrupt the cellular mechanisms that enable tumor growth and metastasis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : sigx1094,Inapplicable
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Signet Therapeutics Receives IND Approval for Targeted Therapy for Diffuse Gastric Cancer
Details : Sigx1094, an investigational small molecule and the first targeted drug candidate for diffuse gastric cancer, has received IND approval from the FDA.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2024
Lead Product(s) : sigx1094,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Juno Pharmaceuticals Pty Ltd
Deal Size : Undisclosed
Deal Type : Financing
Signet Healthcare Partners Completes Growth Equity Investment in Juno Pharmaceuticals Corp.
Details : Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio including Adrenaline Aguettant. Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and sp...
Product Name : Adrenaline Aguettant-Generic
Product Type : Hormone
Upfront Cash : Undisclosed
February 24, 2022
Lead Product(s) : Epinephrine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Juno Pharmaceuticals Pty Ltd
Deal Size : Undisclosed
Deal Type : Financing